Reply: Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

1 citing paper in PubMed.

1. Cardiovascular complications in patients with sickle cell disease.Hematology. American Society of Hematology. Education Program · 2017
   Review

Corrections and comments

• Comment on
  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.2014
• Comment on
  Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption.2014

Authors and funding

13 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as